Evidence map›Paper›PMID 31201175›Full record

ArticleCMAJ open

Impact of the Quebec Alzheimer Plan on the detection and management of Alzheimer disease and other neurocognitive disorders in primary health care: a retrospective study.

Isabelle Vedel, Nadia Sourial, Genevieve Arsenault-Lapierre, Claire Godard-Sebillotte, Howard Bergman

Open access · diamondAbstract read
In one paragraph

Article in CMAJ open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Canadian family physician Medecin de famille canadien · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Isabelle VedelDepartment of Family Medicine (Vedel, Sourial, Godard-Sebillotte, Bergman), McGill University; Lady Davis Institute (Vedel, Sourial, Arsenault-Lapierre), Jewish General Hospital, Montréal, Que. isabelle.vedel@mcgill.ca.
Nadia SourialDepartment of Family Medicine (Vedel, Sourial, Godard-Sebillotte, Bergman), McGill University; Lady Davis Institute (Vedel, Sourial, Arsenault-Lapierre), Jewish General Hospital, Montréal, Que.
Genevieve Arsenault-LapierreDepartment of Family Medicine (Vedel, Sourial, Godard-Sebillotte, Bergman), McGill University; Lady Davis Institute (Vedel, Sourial, Arsenault-Lapierre), Jewish General Hospital, Montréal, Que.
Claire Godard-SebillotteDepartment of Family Medicine (Vedel, Sourial, Godard-Sebillotte, Bergman), McGill University; Lady Davis Institute (Vedel, Sourial, Arsenault-Lapierre), Jewish General Hospital, Montréal, Que.
Howard BergmanDepartment of Family Medicine (Vedel, Sourial, Godard-Sebillotte, Bergman), McGill University; Lady Davis Institute (Vedel, Sourial, Arsenault-Lapierre), Jewish General Hospital, Montréal, Que.
McGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Quebec Alzheimer Plan aims to improve care provided to patients with neurocognitive disorders in Family Medicine Groups (FMGs) (multidisciplinary team-based primary care practices). The objective of this study was to determine changes in the detection and management of neurocognitive disorders following implementation of the plan, in 2014.

methodsThis was a retrospective chart review before and after implementation of the Quebec Alzheimer Plan in 13 FMGs. We reviewed 1919 randomly selected charts of patients aged 75 years or more and 945 randomly selected charts of patients in this age group with neurocognitive disorders. In the first group, selected outcomes were proportion of patients with documentation of cognitive status, documented diagnosis of neurocognitive disorder, documented cognitive testing and referral to a memory clinic. In patients with neurocognitive disorders, the outcomes were number of contacts with an FMG, quality of follow-up score (documented assessments in 10 domains: cognitive testing, functional status, behavioural and psychological symptoms of dementia, weight, caregiver needs, driving status, home care needs, community service needs, absence of anticholinergic medication and management of dementia medications) and proportion referred to a memory clinic.

resultsSignificantly more patients aged 75 or more had documentation of cognitive status in their chart after plan implementation than before implementation (440 [45.1%] v. 351 [37.2%]) (odds ratio [OR] 1.46, 95% confidence interval [CI] 1.18-1.81). No significant changes were found in documented diagnosis of neurocognitive disorders, cognitive testing or referral to a memory clinic. Among patients with neurocognitive disorders, the number of contacts with an FMG (adjusted mean difference 1.6, 95% CI 0.3-2.8) and quality of follow-up score (adjusted mean difference 6.6, 95% CI 3.9-9.2) increased significantly, without significant changes in the number of referrals to a memory clinic.

interpretationThe results suggest that the Quebec Alzheimer Plan is feasible and beneficial in terms of detection and management of neurocognitive disorders, without an increase in referral to specialists. The findings will be used to scale up the Quebec Alzheimer Plan and to develop the Canadian federal dementia strategy.

Identifiers

PMID31201175
PMCPMC6579653
OpenAlexW2951429868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.